Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, Merck KGaA Enter CNS Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, Merck KGaA Enter CNS Development Pact

Evotec AG, through the NEU(2) consortium, has signed an agreement with Merck KGaA to develop pre-clinical candidates for an undisclosed neurological disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG, through the NEU(2) consortium, has signed an agreement with Merck KGaA to develop pre-clinical candidates for an undisclosed neurological disease. Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology. Evotec will apply its drug discovery expertise and technologies to identify small molecules for the selected target to be further optimized and progressed through lead optimization to a pre-clinical candidate.

Dr. Mario Polywka, chief operating officer of Evotec commented: “We are proud to be part of the NEU(2) consortium and we are extremely pleased that Merck KGaA selected Evotec to collaborate on this interesting Drug Discovery Program which is a further recognition of our CNS disease expertise.”

The NEU(2) consortium includes, among others, Merck KGaA, Evotec AG, European ScreeningPort GmbH, Bionamics GmbH, and the University Medical Center Hamburg-Eppendorf, and is the result of a nationwide “BioPharma” strategy competition of The Federal Ministry of Education and Research. The consortium aims to promote partnerships between academic institutions and pharma and bipharma companies in an effort to strengthen the pharmaceutical value chain in Germany. The NEU(2) consortium focuses on the development of novel therapies against neurological diseases with a specific focus on multiple sclerosis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics